Page last updated: 2024-10-21

3-methoxytyrosine and Abnormal Movements

3-methoxytyrosine has been researched along with Abnormal Movements in 1 studies

Research Excerpts

ExcerptRelevanceReference
"The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations."9.14Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. ( Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010)
"The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations."5.14Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. ( Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adamiak, U1
Kaldonska, M1
Klodowska-Duda, G1
Wyska, E1
Safranow, K1
Bialecka, M1
Gawronska-Szklarz, B1

Trials

1 trial available for 3-methoxytyrosine and Abnormal Movements

ArticleYear
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Clinical neuropharmacology, 2010, Volume: 33, Issue:3

    Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide;

2010